LPA and atherosclerosis: While post hoc analyses of FOURIER and ODYSSEY OUTCOMES suggest a potential benefit of Lp(a) lowering in the secondary prevention of ASCVD, data from randomized, controlled cardiovascular outcomes trials with potent Lp(a)-lowering therapies (HORIZON NCT04023552 and OCEAN(a) NCT05581303) are poised to better examine the ability of Lp(a)-lowering to reduce ASCVD risk.